DUBLIN–(BUSINESS WIRE)–The “Global Blood Plasma Derivatives Market Size, Share & Industry Trends Analysis Report by Application, End-user, Type (Immunoglobulin, Albumin, Factor VIII, Factor IX, Hyperimmune Globulin), Regional Outlook and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
The Global Blood Plasma Derivatives Market size is expected to reach $72.5 billion by 2028, rising at a market growth of 9.3% CAGR during the forecast period.
Blood plasma derivatives are specific protein concentrates extracted from plasma using a fractionation technique. Blood plasma derivatives include albumin, factor VIII, immunoglobulin, hyperimmune globulin, factor IX, and fresh frozen. They are commonly used to destroy viruses that trigger bleeding disorders, hepatitis B, hepatitis C, hemophilia A, immunodeficiency, hypogammaglobulinemia, hemophilia B, and human immunodeficiency virus because they are abundant in proteins, salts, minerals, hormones, vitamins, and protease inhibitors.
In addition, blood plasma derivatives aid in boosting nutrition, regulating body temperature and blood coagulation, maintaining osmotic pressure, improving respiration as well as excretion, and balancing acid-base levels. Blood Plasma Derivatives serve a crucial part in maintaining the body’s normal pH balance and transferring nutrients. After fractionating blood plasma, these compounds are commonly utilized to treat a range of disorders. In hospitals, clinics, diagnostic facilities, and blood transfusion centers, blood plasma derivatives are widely preserved.
Plasma derivatives are generated by chromatographic as well as several other fractionation processes from human plasma. Additionally, certain proteins may be isolated from serum. Several plasma proteins (or their mutated variants) are also created utilizing recombinant DNA methods, in which the protein is synthesized by introducing a gene into an expression system.
Essentially, human blood derivatives are the most suitable growth supplement for hMSC development in vitro since they will avoid any infection and immunogenicity of animal origin and aid to create genetically and epigenetically healthy cells and tissue. The autologous serum is a replacement for FBS. It has been observed that autologous serum/plasma preserves the proliferative and differentiation potential of mesenchymal and bone marrow-derived stem cells and enhances cellular and genetic therapy.
Market Growth Factors
A Rise in The Prevalence of Hemophilia Throughout the World
Hemophilia is a hereditary bleeding condition in which the blood fails to effectively clot due to a deficiency or reduction in a clotting factor protein. Hemophilia A, which is caused by a lack of clotting factor VIII, and hemophilia B, which is caused by a lack of clotting factor IX, are the most frequent kinds of hemophilia. Either kind can result in uncontrolled bleeding into organs, muscles, and joints, as well as chronic bleeding after traumas or surgery.
Rapidly Increasing Geriatric Population Throughout the World
In every country throughout the world, the number of aging people is increasing at an alarming rate. According to the United Nations Organization, in 2020 there will be around 727 million individuals globally aged 65 or older. By 2050, its population is projected to more than triple to about 1.5 billion. The proportion of aged individuals in the global population is anticipated to rise from 9.3% in 2020 to 16.0% by 2050. By the middle of the 21st century, one in six individuals across the world will be 65 or older. The phenomenon of population aging refers to the increased incidence and proportion of aged people in the global population.
Marketing Restraining Factor:
Availability of A Number of Affordable Alternatives to Blood Plasma
Since their emergence in the 1940s, proteins produced from human plasma have become vitally essential medicinal products. The technologies of molecular biology have given alternatives to the delivery of natural goods over the past two decades. Recombinant variants of Factor IX and Factor VIII are commercially accessible, and more plasma proteins are undergoing recombinant development. Additionally, genetic engineering gives the possibility to tweak a natural protein to increase its in vitro production efficiency or alter its therapeutic profile. More efficient production techniques, like transgenic animals or plants, may result in less expensive treatments as well as a greater supply of currently scarce items.
Scope of the Study
By Application
- Immunodeficiency Diseases
- Hypogammaglobulinemia
- Hemophilia
- Von Willebrand’s Disease
- Others
By End-user
- Hospitals
- Clinics
- Others
By Type
- Immunoglobulin
- Albumin
- Factor VIII
- Factor IX
- Hyperimmune Globulin
- Others
By Geography
-
North America
- US
- Canada
- Mexico
- Rest of North America
-
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
-
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Biotest AG
- LFB S.A.
- CSL Limited
- Octapharma AG
- Kedrion S.p.A
- Sanofi S.A.
- Fusion Health Care Pvt. Ltd.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Strategies deployed in Blood Plasma Derivatives Market
Chapter 4. Global Blood Plasma Derivatives Market by Application
Chapter 5. Global Blood Plasma Derivatives Market by End-user
Chapter 6. Global Blood Plasma Derivatives Market by Type
Chapter 7. Global Blood Plasma Derivatives Market by Region
Chapter 8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/ugjnaz
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900